What is the dosing range for Noopept?

Noopept is typically dosed at 5mg (low), 10mg (moderate), or 20mg (high) mg, administered 1–3x daily oral or sublingual (8–12 week cycles). These ranges are aggregated from preclinical research and community protocols — not medical dosing guidance.

What are the reported side effects of Noopept?

Reported side effects of Noopept include: Headache (especially without choline supplementation), Irritability, Brain fog at high doses, Insomnia (if taken too late in day), Initial increased anxiety in some users, Mild nausea.

Nootropic

Noopept

Also known as: GVS-111, N-phenylacetyl-L-prolylglycine ethyl ester, omberacetam, N-Phenylacetyl-L-Prolylglycine Ethyl Ester

Share:Share on Reddit

Noopept is a prescription drug in Russia. Research use only in many jurisdictions. Check local regulations.

📚 Content aggregated from:2 peer-reviewed sources·r/Peptides community·PubMed / NCBI

Overview

Dipeptide-derived nootropic developed in Russia and used across Eastern Europe as a cognitive enhancer and neuroprotective agent. Structurally related to piracetam but estimated to be approximately 1000× more potent by weight. Rapidly crosses the blood-brain barrier and is hydrolyzed to the endogenous neuropeptide cycloprolylglycine, which is proposed as its primary active metabolite.

Research Summary

Noopept (GVS-111) enhances AMPA-receptor function and increases expression of BDNF and NGF in the hippocampus and basal forebrain. Its active metabolite cycloprolylglycine acts as an endogenous neuropeptide with anxiolytic and cognition-enhancing properties. Russian clinical trials demonstrate cognitive improvement in subjects with cognitive impairment, with a better tolerability profile than piracetam at equipotent doses.

Dosing Range

low

5mg

moderate

10mg

high

20mg

Units: mg · Frequency: 1–3x daily oral or sublingual (8–12 week cycles)

Dosing ranges are aggregated from preclinical research and community protocols. Not medical dosing guidance.

Administration Routes

Oral (capsule/powder)Sublingual (dissolved under tongue)Intranasal

Reconstitution Notes

Oral: no reconstitution needed. Sublingual: dissolve powder directly under tongue. Intranasal: dissolve in sterile saline at 10mg/mL for nasal administration. Water-soluble at low concentrations.

Step-by-step reconstitution guide →

Supplies you'll need

Insulin Syringes (U-100)Reconstitution Needles Lambda BAC Water Alcohol Prep Pads

Affiliate links — Research Stack may earn a small commission at no extra cost to you.

Reported Side Effects

Headache (especially without choline supplementation)
Irritability
Brain fog at high doses
Insomnia (if taken too late in day)
Initial increased anxiety in some users
Mild nausea

Research Papers

2 peer-reviewed sources

GVS-111 (noopept): pharmacology and cognitive effects in animal models

Pharmaceutical Chemistry Journal1997

Noopept in mild cognitive impairment: clinical trial data

Zhurnal Nevrologii i Psikhiatrii2011

Community Experiences

Aggregated from public forums. Anecdotal — not clinical evidence.

r/Nootropics

Community reports on noopept dosing, choline pairing requirements, and comparison to racetams.

View original thread

r/Peptides

Researcher discussion on noopept's peptide-derived mechanism and sublingual vs. oral bioavailability.

View original thread

Overview

Noopept (GVS-111, now also known as omberacetam) was developed at the Zakusov Institute of Pharmacology in Moscow as an improved analogue of piracetam. The goal was to create a compound with piracetam-like cognitive benefits but active at far lower doses — reducing side effects while maintaining or improving efficacy.

The result was a dipeptide ester structure (N-phenylacetyl-L-prolylglycine ethyl ester) that:

Is absorbed orally and sublingually
Crosses the blood-brain barrier rapidly
Is hydrolyzed to cycloprolylglycine (CPG) — an endogenous dipeptide found naturally in the human brain
CPG is proposed as the true active metabolite responsible for cognitive effects

Noopept is registered as a pharmaceutical drug in Russia (Noopept® tablets, 10mg) and is one of the most widely self-experimented nootropics in the international biohacking community.

Mechanism

AMPA Receptor Potentiation

At the synapse level, noopept and/or cycloprolylglycine enhances AMPA-type glutamate receptor responsiveness:

Increases receptor conductance (current per channel opening)
Enhances long-term potentiation (LTP) — the synaptic strengthening mechanism underlying memory formation
Improves signal-to-noise ratio in hippocampal and cortical circuits

This AMPA potentiation is distinct from piracetam's mechanism (thought to involve membrane fluidity) and explains noopept's much greater potency by weight.

BDNF and NGF Upregulation

Noopept administration increases mRNA expression of:

BDNF in hippocampus: Supports synaptic plasticity, neuron survival, and memory consolidation
NGF in basal forebrain: Supports cholinergic neuron maintenance (the system most depleted in Alzheimer's disease)

These effects are particularly relevant for neuroprotective applications and have generated interest in noopept as a prophylactic cognitive supplement.

Cycloprolylglycine (CPG) as Active Metabolite

CPG is an endogenous mammalian neuropeptide at nanomolar brain concentrations. Research shows:

Anxiolytic properties: CPG modulates GABA-A receptor complex
Nootropic effects: Independent of direct AMPA action
Anti-amnestic activity: Reduces forgetting in scopolamine amnesia models

The prodrug model — noopept → CPG — parallels how many pharmaceutical peptides require metabolic conversion to their active form.

Acetylcholine System Interaction

Noopept preserves cholinergic neurotransmission through:

NGF support for basal forebrain cholinergic neurons
Indirect enhancement of acetylcholine release via improved neural signaling efficiency

This explains why choline supplementation is typically recommended alongside noopept — supporting the cholinergic system reduces headache and brain fog side effects associated with increased demand on the system.

Racetam Comparison

| Compound | Relative potency | Half-life | Main mechanism | |----------|-----------------|-----------|----------------| | Piracetam | 1× | ~5 hours | Membrane fluidity, AMPA | | Aniracetam | ~3–5× | ~1–2 hours | AMPA, mGluR | | Oxiracetam | ~3–4× | ~8 hours | AMPA, NMDA | | Pramiracetam | ~7×| ~5 hours | Choline uptake | | Noopept | ~1000× | ~1 hour (rapid) | AMPA, BDNF/NGF, CPG |